Literature DB >> 27866089

Absence of epithelial atypia in B3-lesions of the breast is associated with decreased risk for malignancy.

Sebastian Mayer1, Gian Kayser2, Gerta Rücker3, Diana Bögner4, Marc Hirschfeld5, Christiane Hug6, Elmar Stickeler7, Gerald Gitsch6, Thalia Erbes6.   

Abstract

INTRODUCTION: Lesions of uncertain malignant potential (B3) represent a heterogeneous group with an overall risk for malignancy of 9.85-35.1% after total resection. Positive predictive values (PPV) for malignancy vary depending on B3 subtype. The aim of this study was to evaluate the PPV for malignancy in B3 lesions and to determine the clinical significance of atypia-dependent sub-classification (a = without epithelial atypia; b = with epithelial atypia) of B3 into B3a and B3b and papillary lesions (PL) in PLa and PLb.
METHODS: 219 patients with histopathologically proven B3 lesions on core needle/vacuum-assisted biopsy who subsequently underwent diagnostic excision biopsy were included in this study. PPVs for malignancy were reported for B3 in general and all B3 sub-categories. Logistic regression analysis identified associations between B3-subgroups and outcome after excision biopsy as well as the impact of clinical and diagnostic findings on excision diagnosis.
RESULTS: The overall PPV rate was 10.0% (22/219). Excision histology exhibited a higher malignancy rate in PLb (2/7; PPV: 28.6%) than in PLa (6/127; PPV: 4.7%) (p = 0.057) and in B3b (12/50; PPV: 24.0%) compared to B3a category (8/165; PPV: 4.8%) (p < 0.001). DISCUSSION: These findings support the necessity of B3 lesion sub-classification into B3a and B3b and of PL into PLa and PLb when considering epithelial atypia. The determination of atypia status represents a relevant factor in risk-stratification for clinical management of B3 lesions. Should future studies using the sub-classification of PL confirm these results, observation may be a safe option for the clinical management of patients with asymptomatic PLa lesions.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atypia; B3 lesion; Breast cancer; DCIS; Lesion of uncertain malignant potential; PPV for malignancy; Papillary lesion

Mesh:

Year:  2016        PMID: 27866089     DOI: 10.1016/j.breast.2016.11.007

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  8 in total

1.  Do clinical and radiologic features help predict malignancy of B3 breast lesions without epithelial atypia (B3a)?

Authors:  Iliana Bednarova; Viviana Londero; Anna Linda; Rossano Girometti; Michele Lorenzon; Sandra Bednarova; Chiara Zuiani
Journal:  Radiol Med       Date:  2018-07-05       Impact factor: 3.469

2.  Effectiveness of percutaneous vacuum-assisted excision (VAE) of breast lesions of uncertain malignant potential (B3 lesions) as an alternative to open surgical biopsy.

Authors:  Elisabetta Giannotti; Jonathan J James; Yan Chen; Rachel Sun; Amanjot Karuppiah; Julie Yemm; Andrew H S Lee
Journal:  Eur Radiol       Date:  2021-06-08       Impact factor: 5.315

3.  Ultrasound-guided 8-Gauge vacuum-assisted excision for selected B3 breast lesions: a preliminary experience.

Authors:  Giovanna Panzironi; Giuliana Moffa; Francesca Galati; Federica Pediconi
Journal:  Radiol Med       Date:  2021-11-20       Impact factor: 3.469

4.  Malignancy Rate and Malignancy Risk Assessment in Different Lesions of Uncertain Malignant Potential in the Breast (B3 Lesions): An Analysis of 192 Cases from a Single Institution.

Authors:  Svjetlana Mohrmann; Anna Maier-Bode; Frederic Dietzel; Petra Reinecke; Natalia Krawczyk; Thomas Kaleta; Ulrike Kreimer; Gerald Antoch; Tanja N Fehm; Katrin Sabine Roth
Journal:  Breast Care (Basel)       Date:  2021-07-01       Impact factor: 2.268

Review 5.  Positive predictive value for malignancy of uncertain malignant potential (B3) breast lesions diagnosed on vacuum-assisted biopsy (VAB): is surgical excision still recommended?

Authors:  Marco Lucioni; Chiara Rossi; Pascal Lomoro; Francesco Ballati; Marianna Fanizza; Alberta Ferrari; Carlos A Garcia-Etienne; Emanuela Boveri; Giulia Meloni; Maria Grazia Sommaruga; Elisa Ferraris; Angioletta Lasagna; Elisabetta Bonzano; Marco Paulli; Adele Sgarella; Giuseppe Di Giulio
Journal:  Eur Radiol       Date:  2020-08-20       Impact factor: 5.315

6.  The value of imaging combined with clinicopathological features in the diagnosis of high-risk breast lesions.

Authors:  Jiayin Zhou; Shiyun Sun; Luyi Lin; Tingting Jiang; Xiaoxin Hu; Yajia Gu; Chao You
Journal:  Gland Surg       Date:  2022-08

7.  Apparent diffusion coefficient values in borderline breast lesions upgraded and not upgraded at definitive histopathological examination after surgical excision.

Authors:  Corrado Tagliati; Paola Piccinni; Paola Ercolani; Elisabetta Marconi; Barbara Franca Simonetti; Gian Marco Giuseppetti; Andrea Giovagnoni
Journal:  Pol J Radiol       Date:  2021-04-30

8.  Elite VABB 13G: A New Ultrasound-Guided Wireless Biopsy System for Breast Lesions. Technical Characteristics and Comparison with Respect to Traditional Core-Biopsy 14-16G Systems.

Authors:  Daniele La Forgia; Alfonso Fausto; Gianluca Gatta; Graziella Di Grezia; Angela Faggian; Annarita Fanizzi; Daniela Cutrignelli; Rosalba Dentamaro; Vittorio Didonna; Vito Lorusso; Raffaella Massafra; Sabina Tangaro; Maria Antonietta Mazzei
Journal:  Diagnostics (Basel)       Date:  2020-05-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.